

## ASX ANNOUNCEMENT

23 June 2021

## Pharmacy Network to Commence Sales of wheezo™

Respiri Limited (ASX:RSH) (“Respiri” or the “Company”), an eHealth SaaS Company supporting respiratory health management is excited to announce the commencement of sales of wheezo™ across 570+ pharmacies within the Sigma Healthcare network Australia-wide.

Sigma is a trusted and respected national wholesaler and the owner of pharmacy brands Amcal, Chemist King, Discount Drug Store, Guardian, Pharmasave & Wholelife. Sigma’s pharmacy offering is built around accessible and affordable healthcare products and programs to support pharmacists in meeting the healthcare needs of their community. The addition of wheezo will further enhance local community services and help patients better manage their asthma.

CEO and Managing Director of Respiri, Mr Marjan Mikel said “Sigma is a well-known and trusted pharmacy business whose brands have a long history in the Australian market, that patients frequent when seeking healthcare management advice. We look forward to a long and mutually beneficial partnership with Sigma’s retail brands that will deliver better health outcomes for patients with asthma”.

The Company is in active discussions with a number of additional pharmacy banner groups, representing a pharmacy footprint of over 2,500 stores across Australia and expects to make further ASX announcements once these discussions are finalised and initial orders have commenced.

Since Q4 CY2020, Respiri has onboarded fourteen (14) pharmacy banner groups, with a total pharmacy network across Australia of approximately 1,600 stores, representing an implied market footprint of approximately 35% based on the total number of ex-hospital community pharmacies across the country.

- ENDS -

For further information, investors and media please contact:

**Mr Marjan Mikel**  
CEO & Managing Director  
Respiri Limited  
P: +61 408 462 873  
E: [marjan@respiri.co](mailto:marjan@respiri.co)

**Mr Nicholas Smedley**  
Executive Chairman  
Respiri Limited  
P: +61 447 074 160  
E: [nicholas@respiri.co](mailto:nicholas@respiri.co)

*This ASX announcement dated 23 June 2021 has been authorised for release by the Board of Directors of Respiri Limited.*

## About Respi Limited

Respi is an e-Health SaaS company supporting respiratory health management. Its world-first technology detects wheeze, a typical symptom of asthma, COPD and respiratory disease to provide an objective measure of airway limitation. wheezo, Respi's innovative technology, comprises an eHealth app combined with a simple, easy to use, handheld device. wheezo is the first smart device to help improve asthma management by monitoring wheeze and documenting symptoms, signs, triggers, weather conditions and medication use. The asthma management platform also facilitates the sharing of data with caregivers, physicians and other health care professionals.

Respi's mission is to help improve quality of life for hundreds of millions of children and adults around the world and dramatically reduce hospital admissions and the economic burden of asthma. Respi Limited's operations are based in Melbourne, Australia.

For additional information about Respi and its products, please visit [www.respi.co](http://www.respi.co)

## About wheezo

Developed in Australia, with the support of respiratory specialists and other healthcare professionals, the innovative wheezo device analyses breath sounds for wheeze, and the eHealth App assists patients with managing their asthma by tracking symptoms, triggers, medication use and geo-specific weather conditions. The platform has been designed to extend asthma management beyond the clinic and make it easy to share information with doctors and make appropriate adjustments to asthma action plans. Better active management may lead to better outcomes and improved quality of life for the asthma patient.

For further information about wheezo, follow the online link <https://wheezo.com>

™ wheezo is a trademark of Respi Limited.

## Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward looking statements are not historical facts but rather are based on Respi current expectations, estimates and projections about the industry in which Respi operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Respi, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. Respi cautions shareholders and prospective shareholders not to place undue reliance on these forward looking statements, which reflect the view of Respi only as of the date of this release. The forward looking statements made in this announcement relate only to events as of the date on which the statements are made. Respi will not undertake any obligation to release publicly any revisions or updates to these forward looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.